Navigation Links
Onyx Pharmaceuticals Provides Status Update on Carfilzomib
Date:10/7/2010

EMERYVILLE, Calif., Oct. 7 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will delay its New Drug Application (NDA) filing for carfilzomib based on a recent meeting with the Chemistry, Manufacturing and Controls (CMC) review division of the U.S. Food and Drug Administration (FDA).  The FDA has requested additional CMC information related to commercial-scale manufacturing of carfilzomib.  Onyx had previously anticipated filing an NDA by the end of 2010 for accelerated approval of carfilzomib and now expects that its NDA filing for accelerated approval could occur as early as mid-year 2011.

The clinical profile of carfilzomib has not changed, and no new safety signals have been observed. The Phase 3 trials are on schedule and actively enrolling patients, and this change is not expected to impact any of the carfilzomib trials or other development plans.

In preparation for commercial-scale production, the company made manufacturing process enhancements in the production of carfilzomib, which are customary when migrating from clinical to commercial-scale manufacturing.  In a recently completed manufacturing-scale run, the company observed minor variations that are believed to be primarily related to equipment temperature variances.  In response to FDA's request, Onyx is providing the agency with additional CMC information.  Onyx has additional data and is generating more information to share as part of the ongoing dialogue with the CMC review division in preparation for an NDA filing.

"We are confident in the clinical and preclinical data package supporting the carfilzomib NDA and in our manufacturing strategy," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "We believe that by providing this supportive data, we will strengthen our NDA package, thus enabling us to bring carfilzom
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 Elekta (NSE:EKTAb) and ... The Christie NHS Foundation Trust ( Manchester, UK ... consortium whose mission is to develop the clinical value ... therapy system. Such a system would, in principle, improve ... targets. "The Christie was an essential ...
(Date:7/22/2014)... 2014  PuraMed BioScience®, Inc., (OTCBB: PMBS), a ... and healthcare products, announced today that the company ... "We are pleased to sponsor Operation ... and Chairman of PuraMed BioScience. "Research shows that ... experience migraines much more frequently than the general ...
(Date:7/22/2014)...  July 22, 2014 The ... Reuters , the world,s leading provider of ... announced Cortellis Clinical Trials Intelligence , ... industry-first milestone with the documentation of more ... professionals with greater and quicker access to ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 2Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 3
... Dec. 7, 2010 LABS Inc., the premier transplant ... that Kevin M. Smith, Chief Operating Officer of the ... has joined the company,s Board of Directors.  Smith brings ... industries. In addition to his current role ...
... 80 percent of the surgeries performed in the U.S. put patients ... a brain monitor is not used by the anesthesiologist. ... book recently published by Dr. Barry Friedberg, an acclaimed anesthesiologist who ... in Michael Jackson,s death. "The simple use of a ...
Cached Medicine Technology:LABS Inc. Adds Life Sciences Industry Veteran Kevin M. Smith to Board of Directors 2Michael Jackson's Death Could Have Been Avoided With a Brain Monitor Says Anesthesiologist 2
(Date:7/22/2014)... Dr. Dental is excited to announce the redesign of ... mind, one of the main differences from the old website ... very easy. Dr. Dental is renowned for having exceptional customer ... affordable, convenient and fun, and the new website mirrors these ... scheduling system right on the home page where a visitor ...
(Date:7/22/2014)... United Benefit Advisors (UBA), the nation's ... McPhearson, an insurance veteran with more than 15 years ... be based in the company's Chicago office. , UBA ... Les chose to accept this important, strategic position with ... many challenges facing UBA and its Partners as we ...
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... that break up blood clots deep in the veins of ... However, one results in a greater risk of bleeding and ... the other treatment, a new study finds. The standard ... (DVT) -- is blood-thinning medications and compression stockings. The other, ...
(Date:7/22/2014)... of Hematology (ASH) will honor Michael DeBaun, MD, MPH, ... Hebbel, MD, of the University of Minnesota Medical School ... their significant research advances in the area of sickle ... the late Ernest Beutler, MD, a past president of ... a two-part lectureship that recognizes major translational advances related ...
(Date:7/22/2014)... E. Marc, Ph.D., director of research at the University ... named by the International Society of Eye Research (ISER) ... Foundation,s 2014 Paul Kayser International Award in Retina Research., ... who has made a significant contribution to the understanding ... presented this week at the ISER Biennial Meeting in ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2
... Fishies is Nordic Naturals newest product for children, the "ultimate ... tasting natural tangerine flavor. Perfect for two-year-olds and up, Nordic ... oil from anchovies and sardines, two sustainable sources of high ... 455 mg of fish oil and offers 136 mg of ...
... Jourdan Urbach, a senior at Roslyn High School, is at ... only 12 seniors nationwide to be named a "national" Toyota Community ... than 8,000 seniors from across the country were nominated by their ... year, honors the top 100 students in the U.S. who are ...
... 23 The European diabetes diagnostics market is poised ... (POC) tests offering tremendous growth potential. Heightened efforts to ... a key driver in market development. For instance, limited ... However, this challenge will be curtailed with more education ...
... ... for the Study of Subtle Energies & Energy Medicine will hold their 19th annual conference ... ... professionals will be interested in attending the 19th annual ISSSEEM Conference that will begin with ...
... ... , ... 23, 2009 -- Big Case Marketing, the global leader in marketing for dentists, dental marketing ... a Boston based coaching and consulting firm for dentists with advanced clinical training, has announced ...
... Dr. Steven Shoshany ... www.LivingwellNewYork.com , to coincide with an exciting new direction he is taking with his office ... ... Chiropractic care in New York City for more than 13 years in his SOHO office. He ...
Cached Medicine News:Health News:Nordic Omega-3 Fishies from Nordic Naturals Offers Quality EPA and DHA for Children with 'Kid Pleasin' Taste 2Health News:Toyota Awards $1 Million in Scholarships to 100 High School Seniors - Roslyn High's Urbach Named One of Only 12 'National' Winners; Receives $20,000 2Health News:Toyota Awards $1 Million in Scholarships to 100 High School Seniors - Roslyn High's Urbach Named One of Only 12 'National' Winners; Receives $20,000 3Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 2Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 3Health News:19th Annual ISSSEEM Conference to Have Richard Bartlett to Discuss the Physics of Miracles: Connecting to the Quantum Field 2Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 2Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 3Health News:New York City Chiropractor Announces New State-Of-The-Art Facility, Website 2
Calcitonin RIA Kit...
... 1200's speed and accuracy allow clinical ... a timely manner - something everyone ... patients. In fact, the Rapidlab 1200 ... just one minute. Its maintenance-free, cartridge-based ...
... The Dornier Medilas D Fibertom is a 60 ... nm wavelength. The use of Diode Power Bar ... system ideal for endovenous laser treatment for varicose ... Medilas D Fibertom also includes unique safety features ...
... test studies the characteristic axies of ... however this 28 hue test ... Case comes with a transparent base ... includes laminated scoring template (approx 8 ...
Medicine Products: